PL2211842T3 - Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym - Google Patents

Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym

Info

Publication number
PL2211842T3
PL2211842T3 PL08841194T PL08841194T PL2211842T3 PL 2211842 T3 PL2211842 T3 PL 2211842T3 PL 08841194 T PL08841194 T PL 08841194T PL 08841194 T PL08841194 T PL 08841194T PL 2211842 T3 PL2211842 T3 PL 2211842T3
Authority
PL
Poland
Prior art keywords
glp
hyperglycemia
diabetes
treatment
dry powder
Prior art date
Application number
PL08841194T
Other languages
English (en)
Inventor
Peter Richardson
Robert A Baughman
Donald Costello
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of PL2211842T3 publication Critical patent/PL2211842T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
PL08841194T 2007-10-24 2008-10-24 Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym PL2211842T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US98236807P 2007-10-24 2007-10-24
US98562007P 2007-11-05 2007-11-05
US3374008P 2008-03-04 2008-03-04
US5212708P 2008-05-09 2008-05-09
PCT/US2008/081218 WO2009055740A2 (en) 2007-10-24 2008-10-24 Method of preventing adverse effects by glp-1
EP08841194.7A EP2211842B1 (en) 2007-10-24 2008-10-24 An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration

Publications (1)

Publication Number Publication Date
PL2211842T3 true PL2211842T3 (pl) 2015-12-31

Family

ID=40546046

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08841194T PL2211842T3 (pl) 2007-10-24 2008-10-24 Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym

Country Status (15)

Country Link
US (4) US8377869B2 (pl)
EP (2) EP2954893A1 (pl)
JP (2) JP2011500850A (pl)
KR (2) KR101736535B1 (pl)
CN (1) CN101969927A (pl)
AU (2) AU2008316634B2 (pl)
BR (1) BRPI0818872A2 (pl)
CA (1) CA2703338A1 (pl)
DK (1) DK2211842T3 (pl)
ES (1) ES2547529T3 (pl)
HU (1) HUE025485T2 (pl)
MX (1) MX2010004510A (pl)
PL (1) PL2211842T3 (pl)
RU (2) RU2474415C2 (pl)
WO (1) WO2009055740A2 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
HUE026797T2 (en) 2004-08-23 2016-07-28 Mannkind Corp Diceto-piperazine salts for drug delivery
KR20120060245A (ko) 2005-09-14 2012-06-11 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
EP2497484A3 (en) 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2009055740A2 (en) 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP3281663B8 (en) 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
AU2010203573A1 (en) 2009-01-08 2011-06-30 Mannkind Corporation Method for treating hyperglycemia with GLP-1
TWI528982B (zh) * 2009-03-04 2016-04-11 曼凱公司 改良的乾粉藥物輸送系統
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
EP3556356B1 (en) * 2009-06-12 2021-05-05 MannKind Corporation Diketopiperazine microparticles with defined isomer content
WO2010144789A2 (en) * 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US8642548B2 (en) 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
AU2015203301B2 (en) * 2009-11-02 2017-05-25 Mannkind Corporation Reactor for producing pharmaceutical particles in a precipitation process
MX357798B (es) 2009-11-02 2018-07-25 Mannkind Corp Aparato y método para la criogranulación de una composición farmacéutica.
CN104801215B (zh) 2009-11-02 2017-11-17 曼康公司 以沉淀过程产生药物颗粒的反应器
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
AU2011271097B2 (en) 2010-06-21 2014-11-27 Mannkind Corporation Dry powder drug delivery system and methods
CN103200940A (zh) * 2010-11-09 2013-07-10 曼金德公司 用于治疗偏头痛的包含血清素受体激动剂和二酮哌嗪的组合物
CN105667994B (zh) 2011-04-01 2018-04-06 曼金德公司 用于药物药盒的泡罩包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
KR20140095483A (ko) 2011-10-24 2014-08-01 맨카인드 코포레이션 통증을 치료하기 위한 방법 및 조성물
DK2872205T3 (en) 2012-07-12 2017-02-27 Mannkind Corp DRY POWDER FORMAL ADMINISTRATION SYSTEM
JP2015526523A (ja) * 2012-08-29 2015-09-10 マンカインド コーポレイション 高血糖症の治療のための方法および組成物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
WO2015010092A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
AU691361B2 (en) 1994-12-01 1998-05-14 Toyama Chemical Co. Ltd. Novel 2,3-diketopiperazine derivative or salt thereof
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
US5766620A (en) 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
WO1997031626A1 (fr) 1996-02-27 1997-09-04 Teijin Limited Composition pulverulente destinee a une adminstration nasale
JPH1053765A (ja) * 1996-06-04 1998-02-24 Denso Corp スメクチック液晶組成物及び液晶セル
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
JP3020141B2 (ja) 1996-10-07 2000-03-15 株式会社富士薬品 経鼻投与用製剤
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2001504105A (ja) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１ペプチドの利用
CA2283834A1 (en) 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１製剤
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
KR100611025B1 (ko) 1998-08-26 2006-08-10 데이진 가부시키가이샤 분말상 경비 조성물
AR022368A1 (es) * 1998-08-28 2002-09-04 Lilly Co Eli Procedimiento para administrar peptidos insulinotropicos
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
ES2261195T3 (es) 1999-04-05 2006-11-16 Mannkind Corporation Metodo de formacion de particulas finas.
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
SI1133312T1 (sl) 1999-06-21 2008-02-29 Lilly Co Eli Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina
PT1808438E (pt) 1999-06-29 2015-01-14 Mannkind Corp Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) * 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
US6468507B1 (en) 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US6447750B1 (en) 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
ATE346093T1 (de) 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU6895801A (en) 2000-07-04 2002-01-14 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
MXPA03005135A (es) 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
AU2002254567B2 (en) 2001-04-11 2007-10-11 Bristol-Myers Squibb Company Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
US7232897B2 (en) 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
MXPA04001525A (es) 2001-08-23 2004-05-31 Lilly Co Eli Analogos de peptido -1 similar al glucagon.
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
JP2005508360A (ja) 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１およびインスリンの二相混合物
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040121964A1 (en) * 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
JP3903061B2 (ja) * 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
KR20070008720A (ko) * 2004-05-06 2007-01-17 에미스페어 테크놀로지스, 인코포레이티드 습윤 헤파린의 고체 투여형
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
EP1781254A2 (en) 2004-08-23 2007-05-09 Mannkind Corporation Pulmonary delivery of inhibitors of phosphodiesterase type 5
HUE026797T2 (en) 2004-08-23 2016-07-28 Mannkind Corp Diceto-piperazine salts for drug delivery
EP1827381A1 (en) * 2004-12-03 2007-09-05 Mederio AG A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
SE0402976L (sv) * 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
WO2006086107A2 (en) * 2005-01-10 2006-08-17 Mannkind Corporation Methods and compositions for minimizing accrual of inhalable insulin in the lungs
WO2007030706A1 (en) 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
KR20120060245A (ko) 2005-09-14 2012-06-11 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
WO2007075534A2 (en) * 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
EP2497484A3 (en) * 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
EP2010155A2 (en) * 2006-04-14 2009-01-07 MannKind Corporation Glucagon-like peptide 1(glp-1) pharmaceutical formulations
AU2008216265B2 (en) * 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20100090692A (ko) 2007-10-24 2010-08-16 맨카인드 코포레이션 활성제의 전달
WO2009055740A2 (en) 2007-10-24 2009-04-30 Mannkind Corporation Method of preventing adverse effects by glp-1
EP2060268A1 (en) 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides

Also Published As

Publication number Publication date
KR20100093055A (ko) 2010-08-24
RU2012146344A (ru) 2014-05-10
KR101736502B1 (ko) 2017-05-16
WO2009055740A2 (en) 2009-04-30
EP2211842B1 (en) 2015-08-12
MX2010004510A (es) 2010-07-02
AU2014202731A1 (en) 2014-06-12
KR101736535B1 (ko) 2017-05-16
CA2703338A1 (en) 2009-04-30
US20200147219A1 (en) 2020-05-14
AU2008316634A1 (en) 2009-04-30
BRPI0818872A2 (pt) 2015-05-05
US20130125886A1 (en) 2013-05-23
EP2211842A2 (en) 2010-08-04
JP2011500850A (ja) 2011-01-06
HUE025485T2 (en) 2016-02-29
RU2474415C2 (ru) 2013-02-10
JP2015013892A (ja) 2015-01-22
RU2010120666A (ru) 2011-11-27
KR20130123467A (ko) 2013-11-12
ES2547529T3 (es) 2015-10-07
US8377869B2 (en) 2013-02-19
WO2009055740A3 (en) 2009-06-11
DK2211842T3 (en) 2015-09-21
AU2008316634B2 (en) 2014-02-27
US20090110647A1 (en) 2009-04-30
CN101969927A (zh) 2011-02-09
US20220387593A1 (en) 2022-12-08
EP2954893A1 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
PL2211842T3 (pl) Preparat suchego proszku do inhalacji zawierający glp-1 do stosowania w leczeniu hiperglikemii i cukrzycy w podawaniu płucnym
IL215276A (en) Dry powdered compositions and their use in the preparation of drugs for the treatment of lung disease
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL226101A (en) Capsule Formulations of N- Tert-Butyl-3 - [(5-Methyl-2 - {[4- (2-Pyrrolidine-1-Illethoxy) Phenyl [Amino {Pyrimidine-4-Il) Amino] Benzinsulfonamide and Their Use in the Preparation of Drugs In myelofibrosis
IL219309A (en) History of glycoside, including pharmaceutical preparations and their use in the preparation of diabetes medications
EP3281663B8 (en) Breath powered dry powder inhaler for drug delivery
IL204887A (en) Acetamide History, Pharmaceuticals Containing Them, Methods of Preparing and Using It in the Preparation of Diabetes Medications
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
IL202515A (en) Thyroid-like compounds and their use in the preparation of drugs for the treatment of @ metabolic diseases
HK1166263A1 (en) Use of a foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
IL213623A (en) Compounds 4-piperazine-1-yl benzamide are produced and used in the preparation of a drug
IL221573A (en) Imidazoquinolines and their use in the preparation of drugs for the treatment of proliferative and inflammatory and obstructive pulmonary diseases
IL213622A (en) Benzamide compounds are being used and their use in making a drug
WO2010011439A3 (en) Gip-based mixed agonists for treatment of metabolic disorders and obesity
IL216876A (en) Cationic lipid, lipid formulations including it and their use in the preparation of cellular therapeutic agents
PL2731947T3 (pl) Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
EP2441453A4 (en) PHARMACEUTICAL COMPOSITION FOR HUMAN AND ANIMAL MEDICINE OPHTHALMOLOGY
EP2275108A4 (en) PHARMACEUTICAL PREPARATION COMPRISING A DPP-IV INHIBITOR AND OTHER DIABETES THERAPEUTIC AGENTS IN CONCOMITANT OR COMBINED FORM
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
IL211946A (en) Annotated (2-Hydroxy-2-Phenyl-1-Pyrrolidine-1-Illmethyl-Ethyl) -Carbamic Acid Phenyl Ester
IL207972A (en) History of pyridine-2-ram, pharmaceuticals containing them and their use in the preparation of medicines
IL212966A (en) Pyrazole-1-yl-methyl-cyclohexyl-acetic acid compounds, pharmaceutical preparations containing them, use of pharmaceutical preparation compounds and compounds for use in treatment method
HK1167348A1 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
ZA201007060B (en) Pyrazinone derivatives as insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes